Deal to close by the 8th. CALGARY, June 30, 2015 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that holders ("Shareholders") of common shares of Resverlogix have approved the resolutions relating to: (i) a private placement to Eastern Capital Limited of 5,600,000 units at a price of $2.67 per unit (the "Eastern Private Placement"), each unit being comprised of one common share and 0.075358 common share purchase warrants, for aggregate proceeds of approximately CAD$15 million; and (ii) the amendment to Resverlogix's articles to change the rights, privileges, restrictions and conditions in respect of the Royalty Preferred Shares (the "Royalty Preferred Share Amendment"), as more particularly described in the management information circular dated May 29, 2015. Obtaining shareholder approval for the Eastern Private Placement and Royalty Preferred Share Amendment was necessary in order for Resverlogix to proceed with its previously announced licensing and equity arrangement with Shenzhen Hepalink Pharmaceutical Co., Ltd. (the "Hepalink Transaction"). The resolutions relating to the Eastern Private Placement and the Royalty Preferred Share Amendment were approved by approximately 98.0% and 98.7%, respectively, of the votes cast by Shareholders at the special meeting of Shareholders held earlier today. The Royalty Preferred Share Amendment has also been approved by Zenith Epigenetics Corp. as the sole holder of the Royalty Preferred Shares. Resverlogix expects that closing of the Hepalink Transaction and the Eastern Private Placement will occur on or before July 8, 2015.